Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia
oleh: Adriana Seber, Claudio Galvão de CastroJunior, Lucila N. Kerbauy, Alexandre V. Hirayama, Carmem Bonfim, Juliana Folloni Fernandes, Mair Souza, Rony Schafell, Samir Nabhan, Sandra Regina Loggetto, Belinda Pinto Simões, Vanderson Rocha, Marcos de Lima, Renato L. Guerino-Cunha, Henrique Bittencourt
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2021-11-01 |
Deskripsi
Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytokine release syndrome (CRS) and neurological toxicities (ICANS). This manuscript aims to provide a consensus of specialists in the fields of Hematology Oncology and Cellular Therapy to make recommendations on the current scenario of the use of CAR-T cells in patients with ALL.